{"transactions":[{"id":678969,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:08:55.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":375000,"derivative":{"exercise_price":1.52,"expiration_date":"2036-08-20","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001610717-26-000383","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000383/form4.xml","form_type":"4"}},{"id":942308,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:18:53.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":750000,"derivative":{"exercise_price":2.33,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001610717-26-000010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000010/form4.xml","form_type":"4"}},{"id":1129468,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:59.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":500000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-25-079924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079924/ownership.xml","form_type":"4"}},{"id":1129467,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:59.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":400000,"derivative":{"exercise_price":0.72,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-079924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079924/ownership.xml","form_type":"4"}},{"id":1129466,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:59.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-25-079924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079924/ownership.xml","form_type":"4"}},{"id":1129465,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:59.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-079924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079924/ownership.xml","form_type":"4"}},{"id":1264081,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":400000,"derivative":{"exercise_price":1.69,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-022316","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022316/ownership.xml","form_type":"4"}},{"id":1264080,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":12.97,"expiration_date":"2033-12-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-022316","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022316/ownership.xml","form_type":"4"}},{"id":1264079,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":500000,"derivative":{"exercise_price":1.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-25-022316","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022316/ownership.xml","form_type":"4"}},{"id":1714594,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-12T23:16:39.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":400000,"derivative":{"exercise_price":12.97,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001610717-23-000398","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071723000398/form4.xml","form_type":"4"}},{"id":1978947,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Restricted Stock Units","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":65850,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a \"Company RSU\") that was granted prior to the\ndate of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an \"Accelerated 2023 RSU,\" was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a \"Cancelled 2023 RSU\" was canceled and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a \"Company RSU\") that was granted prior to the\ndate of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an \"Accelerated 2023 RSU,\" was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a \"Cancelled 2023 RSU\" was canceled and had no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":65850},"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":1978946,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":1978945,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":23700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":34.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":23700},"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":1978944,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":24337,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":24337},"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":1978943,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":10063,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":10063},"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":1978942,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":15900,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise\nprice per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":26.75,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":15900},"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":1978941,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2023-03-02T16:44:47.000Z","date":"2023-03-02","kind":"other","acquired":false,"shares":3296,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger\nAgreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the \"Closing Amount\")"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) plus one non-tradeable contractual contingent value right (\"CVR\" and each CVR together with the Closing Amount, the \"Offer Price\"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the \"CVR Agreement\") on or prior to December 31, 2027\n(the \"Milestone\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger\nAgreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the \"Closing Amount\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) plus one non-tradeable contractual contingent value right (\"CVR\" and each CVR together with the Closing Amount, the \"Offer Price\"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the \"CVR Agreement\") on or prior to December 31, 2027\n(the \"Milestone\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-014741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014741/doc4.xml","form_type":"4"}},{"id":2043557,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2023-01-27T17:26:32.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, 6.25% of the shares every three months thereafter beginning on April 19, 2024 and ending on January 19, 2025, and 12.5% of the shares every three months thereafter beginning on April 19, 2025 and ending on January 19, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 3,296 shares of common stock and 65,850 restricted stock units."}],"balance_after":69146,"source":{"system":"sec-edgar","filing":"0001209191-23-005335","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123005335/doc4a.xml","form_type":"4/A","original_submission_date":"2023-01-25"}},{"id":2046265,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2023-01-25T20:09:53.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, with the remainder vesting in equal installments every three months thereafter beginning on April 19, 2024 and ending on January 19, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 3,296 shares of common stock and 65,850 restricted stock units."}],"balance_after":69146,"source":{"system":"sec-edgar","filing":"0001209191-23-004950","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004950/doc4.xml","form_type":"4"}},{"id":2048524,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2023-01-23T17:10:15.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":228,"price":43.8,"value":9986.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 3,296 shares of common stock and 10,850 restricted stock units."}],"balance_after":14146,"source":{"system":"sec-edgar","filing":"0001209191-23-004451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004451/doc4.xml","form_type":"4"}},{"id":2049597,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2023-01-20T16:05:36.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":938,"price":43.9044,"value":41182.3272,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 2,867 shares of common stock and 11,507 restricted stock units. Includes 381 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on November 30, 2022."}],"balance_after":14374,"source":{"system":"sec-edgar","filing":"0001209191-23-004223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004223/doc4.xml","form_type":"4"}},{"id":2132235,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-10-25T16:00:40.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":456,"price":19.3963,"value":8844.7128,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.2697 to $19.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents 724 shares of common stock and 14,207 restricted stock units."}],"balance_after":14931,"source":{"system":"sec-edgar","filing":"0001209191-22-054490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122054490/doc4.xml","form_type":"4"}},{"id":2132234,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-10-25T16:00:40.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":96,"price":19.5376,"value":1875.6096,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 1,180 shares of common stock and 14,207 restricted stock units."}],"balance_after":15387,"source":{"system":"sec-edgar","filing":"0001209191-22-054490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122054490/doc4.xml","form_type":"4"}},{"id":2132233,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-10-25T16:00:40.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":104,"price":19.5764,"value":2035.9456,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 1,276 shares of common stock and 14,207 restricted stock units."}],"balance_after":15483,"source":{"system":"sec-edgar","filing":"0001209191-22-054490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122054490/doc4.xml","form_type":"4"}},{"id":2202621,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-07-25T16:12:26.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":220,"price":23.6555,"value":5204.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents 724 shares of common stock and 14,863 restricted stock units."}],"balance_after":15587,"source":{"system":"sec-edgar","filing":"0001209191-22-043100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122043100/doc4.xml","form_type":"4"}},{"id":2202620,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-07-25T16:12:26.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":93,"price":24.395,"value":2268.735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents 944 shares of common stock and 14,863 restricted stock units."}],"balance_after":15807,"source":{"system":"sec-edgar","filing":"0001209191-22-043100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122043100/doc4.xml","form_type":"4"}},{"id":2202619,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-07-25T16:12:26.000Z","date":"2022-07-22","kind":"sale","acquired":false,"shares":238,"price":24.45,"value":5819.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Represents 724 shares of common stock and 15,176 restricted stock units."}],"balance_after":15900,"source":{"system":"sec-edgar","filing":"0001209191-22-043100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122043100/doc4.xml","form_type":"4"}},{"id":2202618,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-07-25T16:12:26.000Z","date":"2022-07-22","kind":"sale","acquired":false,"shares":106,"price":24.6773,"value":2615.7938,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 962 shares of common stock and 15,176 restricted stock units.  Includes 236 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2022."}],"balance_after":16138,"source":{"system":"sec-edgar","filing":"0001209191-22-043100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122043100/doc4.xml","form_type":"4"}},{"id":2291013,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-04-25T16:38:59.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":91,"price":33.4001,"value":3039.4091,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents 488 shares of common stock and 15,520 restricted stock units."}],"balance_after":16008,"source":{"system":"sec-edgar","filing":"0001209191-22-025522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122025522/doc4.xml","form_type":"4"}},{"id":2291012,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-04-25T16:38:59.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":221,"price":33.4397,"value":7390.1737,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Represents 579 shares of common stock and 15,520 restricted stock units."}],"balance_after":16099,"source":{"system":"sec-edgar","filing":"0001209191-22-025522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122025522/doc4.xml","form_type":"4"}},{"id":2291011,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-04-25T16:38:59.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":103,"price":32.9257,"value":3391.3471,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 488 shares of common stock and 15,832 restricted stock units."}],"balance_after":16320,"source":{"system":"sec-edgar","filing":"0001209191-22-025522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122025522/doc4.xml","form_type":"4"}},{"id":2291010,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-04-25T16:38:59.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":240,"price":33.07,"value":7936.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 591 shares of common stock and 15,832 restricted stock units."}],"balance_after":16423,"source":{"system":"sec-edgar","filing":"0001209191-22-025522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122025522/doc4.xml","form_type":"4"}},{"id":2426481,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-01-25T16:39:21.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":1176,"price":24.9443,"value":29334.4968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Represents 488 shares of common stock and 16,175 restricted stock units."}],"balance_after":16663,"source":{"system":"sec-edgar","filing":"0001209191-22-004809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004809/doc4.xml","form_type":"4"}},{"id":2426480,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-01-25T16:39:21.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":96,"price":25.089,"value":2408.544,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 1,664 shares of common stock and 16,175 restricted stock units."}],"balance_after":17839,"source":{"system":"sec-edgar","filing":"0001209191-22-004809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004809/doc4.xml","form_type":"4"}},{"id":2426479,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-01-25T16:39:21.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":416,"price":24.8822,"value":10350.9952,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.7811 to $24.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 1,447 shares of common stock and 16,488 restricted stock units."}],"balance_after":17935,"source":{"system":"sec-edgar","filing":"0001209191-22-004809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004809/doc4.xml","form_type":"4"}},{"id":2430016,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-20T16:52:35.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":15900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026."}],"balance_after":15900,"derivative":{"exercise_price":26.75,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":15900},"source":{"system":"sec-edgar","filing":"0001209191-22-004060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004060/doc4.xml","form_type":"4"}},{"id":2430015,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2022-01-20T16:52:35.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":10800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 488 shares of common stock and 17,863 restricted stock units. Includes 196 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2021."}],"balance_after":18351,"source":{"system":"sec-edgar","filing":"0001209191-22-004060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004060/doc4.xml","form_type":"4"}},{"id":2535424,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-10-25T18:30:49.000Z","date":"2021-10-25","kind":"sale","acquired":false,"shares":217,"price":29.21,"value":6338.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Represents 292 shares of common stock and 7,063 restricted stock units."}],"balance_after":7355,"source":{"system":"sec-edgar","filing":"0001209191-21-061556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121061556/doc4.xml","form_type":"4"}},{"id":2535423,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-10-25T18:30:49.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":95,"price":28.8508,"value":2740.826,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.8350 to $28.8974, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 509 shares of common stock and 7,063 restricted stock units."}],"balance_after":7572,"source":{"system":"sec-edgar","filing":"0001209191-21-061556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121061556/doc4.xml","form_type":"4"}},{"id":2624750,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-07-26T16:05:18.000Z","date":"2021-07-23","kind":"sale","acquired":false,"shares":223,"price":31.43,"value":7008.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 292 shares of common stock and 7,375 restricted stock units."}],"balance_after":7667,"source":{"system":"sec-edgar","filing":"0001209191-21-048160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121048160/doc4.xml","form_type":"4"}},{"id":2624749,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-07-26T16:05:18.000Z","date":"2021-07-22","kind":"sale","acquired":false,"shares":90,"price":34.13,"value":3071.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 515 shares of common stock and 7,375 restricted stock units."}],"balance_after":7890,"source":{"system":"sec-edgar","filing":"0001209191-21-048160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121048160/doc4.xml","form_type":"4"}},{"id":2653164,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-25","kind":"exercise","acquired":false,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021."}],"balance_after":24337,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653163,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-24","kind":"exercise","acquired":false,"shares":863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021."}],"balance_after":30637,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":863},"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653162,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-24","kind":"exercise","acquired":false,"shares":9137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."}],"balance_after":10063,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":9137},"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653161,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":6300,"price":36.22,"value":228186.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 292 shares of common stock and 7,688 restricted stock units. Includes 131 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2021."}],"balance_after":7980,"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653160,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-25","kind":"exercise","acquired":true,"shares":6300,"price":24.67,"value":155421.0,"ownership":{"direct":true},"balance_after":14280,"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653159,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-24","kind":"sale","acquired":false,"shares":10000,"price":36.38,"value":363800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":7980,"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653158,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-24","kind":"exercise","acquired":true,"shares":863,"price":24.67,"value":21290.21,"ownership":{"direct":true},"balance_after":17980,"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2653157,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-06-28T16:01:51.000Z","date":"2021-06-24","kind":"exercise","acquired":true,"shares":9137,"price":24.04,"value":219653.48,"ownership":{"direct":true},"balance_after":17117,"source":{"system":"sec-edgar","filing":"0001209191-21-043467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121043467/doc4.xml","form_type":"4"}},{"id":2739435,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-04-26T18:13:28.000Z","date":"2021-04-23","kind":"sale","acquired":false,"shares":222,"price":32.32,"value":7175.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 161 shares of common stock and 7,688 restricted stock units."}],"balance_after":7849,"source":{"system":"sec-edgar","filing":"0001209191-21-028384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121028384/doc4.xml","form_type":"4"}},{"id":2739434,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-04-26T18:13:28.000Z","date":"2021-04-22","kind":"sale","acquired":false,"shares":90,"price":31.75,"value":2857.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 383 shares of common stock and 7,688 restricted stock units."}],"balance_after":8071,"source":{"system":"sec-edgar","filing":"0001209191-21-028384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121028384/doc4.xml","form_type":"4"}},{"id":2760637,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T20:55:31.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."}],"balance_after":19200,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0001209191-21-024891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121024891/doc4.xml","form_type":"4"}},{"id":2760636,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-04-02T20:55:31.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":300,"price":36.1567,"value":10847.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Includes 72 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2019; 87 shares of common stock acquired under the ESPP on November 30, 2019; and 96 shares of common stock acquired under the ESPP on May 31, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 161 shares of common stock and 8,000 restricted stock units."}],"balance_after":8161,"source":{"system":"sec-edgar","filing":"0001209191-21-024891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121024891/doc4.xml","form_type":"4"}},{"id":2760635,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-04-02T20:55:31.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":300,"price":24.04,"value":7212.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 461 shares of common stock and 8,000 restricted stock units."}],"balance_after":8461,"source":{"system":"sec-edgar","filing":"0001209191-21-024891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121024891/doc4.xml","form_type":"4"}},{"id":2760634,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-04-02T20:55:31.000Z","date":"2021-03-31","kind":"sale","acquired":false,"shares":1426,"price":35.0417,"value":49969.4642,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Includes 72 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2019; 87 shares of common stock acquired under the ESPP on November 30, 2019; and 96 shares of common stock acquired under the ESPP on May 31, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 161 shares of common stock and 8,000 restricted stock units."}],"balance_after":8161,"source":{"system":"sec-edgar","filing":"0001209191-21-024891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121024891/doc4.xml","form_type":"4"}},{"id":2897461,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-25T17:44:26.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":23700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025."}],"balance_after":23700,"derivative":{"exercise_price":34.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":23700},"source":{"system":"sec-edgar","filing":"0001209191-21-005162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005162/doc4.xml","form_type":"4"}},{"id":2897460,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-01-25T17:44:26.000Z","date":"2021-01-22","kind":"sale","acquired":false,"shares":110,"price":34.62,"value":3808.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents 1,332 shares of common stock and 8,000 restricted stock units."}],"balance_after":9332,"source":{"system":"sec-edgar","filing":"0001209191-21-005162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005162/doc4.xml","form_type":"4"}},{"id":2897459,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2021-01-25T17:44:26.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 1,129 shares of common stock and 8,313 restricted stock units. Includes 161 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2020."}],"balance_after":9442,"source":{"system":"sec-edgar","filing":"0001209191-21-005162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005162/doc4.xml","form_type":"4"}},{"id":3000534,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2020-10-23T16:19:09.000Z","date":"2020-10-22","kind":"sale","acquired":false,"shares":89,"price":34.71,"value":3089.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 968 shares of common stock and 2,813 restricted stock units."}],"balance_after":3781,"source":{"system":"sec-edgar","filing":"0001209191-20-055674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120055674/doc4.xml","form_type":"4"}},{"id":3034178,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-10T20:54:51.000Z","date":"2020-09-08","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."}],"balance_after":19500,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-20-050081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120050081/doc4.xml","form_type":"4"}},{"id":3034177,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2020-09-10T20:54:51.000Z","date":"2020-09-08","kind":"sale","acquired":false,"shares":4000,"price":45.55,"value":182200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 745 shares of common stock and 3,125 restricted stock units."}],"balance_after":3870,"source":{"system":"sec-edgar","filing":"0001209191-20-050081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120050081/doc4.xml","form_type":"4"}},{"id":3034176,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2020-09-10T20:54:51.000Z","date":"2020-09-08","kind":"exercise","acquired":true,"shares":3500,"price":24.04,"value":84140.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents 4,745 shares of common stock and 3,125 restricted stock units."}],"balance_after":7870,"source":{"system":"sec-edgar","filing":"0001209191-20-050081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120050081/doc4.xml","form_type":"4"}},{"id":3076799,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2020-07-23T16:23:03.000Z","date":"2020-07-22","kind":"sale","acquired":false,"shares":91,"price":25.8,"value":2347.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 1,245 shares of common stock and 3,125 restricted stock units."}],"balance_after":4370,"source":{"system":"sec-edgar","filing":"0001209191-20-043475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120043475/doc4.xml","form_type":"4"}},{"id":3170038,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2020-04-24T17:20:11.000Z","date":"2020-04-22","kind":"sale","acquired":false,"shares":92,"price":17.68,"value":1626.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 1,023 shares of common stock and 3,438 restricted stock units."}],"balance_after":4461,"source":{"system":"sec-edgar","filing":"0001209191-20-025642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120025642/doc4.xml","form_type":"4"}},{"id":3303828,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-23T19:22:18.000Z","date":"2020-01-21","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021."}],"balance_after":31500,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001209191-20-004740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120004740/doc4.xml","form_type":"4"}},{"id":3303827,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2020-01-23T19:22:18.000Z","date":"2020-01-22","kind":"sale","acquired":false,"shares":447,"price":23.97,"value":10714.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.95 to $24.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 803 shares of common stock and 3,750 restricted stock units."}],"balance_after":4553,"source":{"system":"sec-edgar","filing":"0001209191-20-004740","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120004740/doc4.xml","form_type":"4"}},{"id":3687865,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-24T18:45:51.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."}],"balance_after":23000,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-19-005239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919119005239/doc4.xml","form_type":"4"}},{"id":3687864,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2019-01-24T18:45:51.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-005239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919119005239/doc4.xml","form_type":"4"}},{"id":3898100,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":20889,"kind":"person","name":"Duncan Jason","position":1,"cik":"0001741553","reported_name":"Duncan Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T16:12:21.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on June 8, 2019 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on June 30, 2019 and ending on March 31, 2022."}],"balance_after":37500,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-18-036914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118036914/doc4.xml","form_type":"4"}}]}